BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36815731)

  • 1. Bioorthogonal-Activated In Situ Vaccine Mediated by a COF-Based Catalytic Platform for Potent Cancer Immunotherapy.
    Sun M; Liu Z; Wu L; Yang J; Ren J; Qu X
    J Am Chem Soc; 2023 Mar; 145(9):5330-5341. PubMed ID: 36815731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoscale Metal-Organic Frameworks for Cancer Immunotherapy.
    Ni K; Luo T; Nash GT; Lin W
    Acc Chem Res; 2020 Sep; 53(9):1739-1748. PubMed ID: 32808760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioorthogonal/Ultrasound Activated Oncolytic Pyroptosis Amplifies
    Xu X; Zheng J; Liang N; Zhang X; Shabiti S; Wang Z; Yu S; Pan ZY; Li W; Cai L
    ACS Nano; 2024 Apr; 18(13):9413-9430. PubMed ID: 38522084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanomedicines for an Enhanced Immunogenic Cell Death-Based
    Zhao C; Wang C; Shan W; Wang Z; Chen X; Deng H
    Acc Chem Res; 2024 Mar; 57(6):905-918. PubMed ID: 38417027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Photodynamic Therapy Combined with Antihypoxic Signaling and CpG Adjuvant as an In Situ Tumor Vaccine Based on Metal-Organic Framework Nanoparticles to Boost Cancer Immunotherapy.
    Cai Z; Xin F; Wei Z; Wu M; Lin X; Du X; Chen G; Zhang D; Zhang Z; Liu X; Yao C
    Adv Healthc Mater; 2020 Jan; 9(1):e1900996. PubMed ID: 31746153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.
    Huang L; Rong Y; Tang X; Yi K; Qi P; Hou J; Liu W; He Y; Gao X; Yuan C; Wang F
    Mol Cancer; 2022 Feb; 21(1):45. PubMed ID: 35148751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Black porous silicon as a photothermal agent and immunoadjuvant for efficient antitumor immunotherapy.
    Xu W; Pang C; Song C; Qian J; Feola S; Cerullo V; Fan L; Yu H; Lehto VP
    Acta Biomater; 2022 Oct; 152():473-483. PubMed ID: 36087872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Situ Dendritic Cell Vaccine for Effective Cancer Immunotherapy.
    Yang W; Zhu G; Wang S; Yu G; Yang Z; Lin L; Zhou Z; Liu Y; Dai Y; Zhang F; Shen Z; Liu Y; He Z; Lau J; Niu G; Kiesewetter DO; Hu S; Chen X
    ACS Nano; 2019 Mar; 13(3):3083-3094. PubMed ID: 30835435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Injectable thermosensitive hydrogel to enhance the photothermal ablation and systemic immunotherapy of breast tumors.
    Qin T; Li R; Jin H; Wang Y; Feng L
    Biomater Sci; 2022 Oct; 10(20):6003-6012. PubMed ID: 36053224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hollow Aluminum Hydroxide Modified Silica Nanoadjuvants with Amplified Immunotherapy Effects through Immunogenic Cell Death Induction and Antigen Release.
    Tan J; Ding B; Zheng P; Chen H; Ma P; Lin J
    Small; 2022 Aug; 18(34):e2202462. PubMed ID: 35896867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In situ photothermal nano-vaccine based on tumor cell membrane-coated black phosphorus-Au for photo-immunotherapy of metastatic breast tumors.
    Huang D; Wu T; Lan S; Liu C; Guo Z; Zhang W
    Biomaterials; 2022 Oct; 289():121808. PubMed ID: 36137415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational Design of T-Cell- and B-Cell-Based Therapeutic Cancer Vaccines.
    Li WH; Su JY; Li YM
    Acc Chem Res; 2022 Sep; 55(18):2660-2671. PubMed ID: 36048514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dendritic cell vaccine for the effective immunotherapy of breast cancer.
    Ni J; Song J; Wang B; Hua H; Zhu H; Guo X; Xiong S; Zhao Y
    Biomed Pharmacother; 2020 Jun; 126():110046. PubMed ID: 32145586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Microenvironment-Activated Hydrogel Platform with Programmed Release Property Evokes a Cascade-Amplified Immune Response against Tumor Growth, Metastasis and Recurrence.
    Gong S; Liang X; Zhang M; Li L; He T; Yuan Y; Li X; Liu F; Yang X; Shen M; Wu Q; Gong C
    Small; 2022 Dec; 18(50):e2107061. PubMed ID: 36323618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-Atom Catalysts Mediated Bioorthogonal Modulation of N
    Sun M; Liu X; Liu Z; Zhang W; Li G; Ren J; Qu X
    J Am Chem Soc; 2024 Mar; 146(12):8216-8227. PubMed ID: 38486429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
    Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crizotinib prodrug micelles co-delivered doxorubicin for synergistic immunogenic cell death induction on breast cancer chemo-immunotherapy.
    Liang Q; Lan Y; Li Y; Cao Y; Li J; Liu Y
    Eur J Pharm Biopharm; 2022 Aug; 177():260-272. PubMed ID: 35863668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasmon-Driven Catalytic Chemotherapy Augments Cancer Immunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway.
    Ding Y; Sun Z; Gao Y; Zhang S; Yang C; Qian Z; Jin L; Zhang J; Zeng C; Mao Z; Wang W
    Adv Mater; 2021 Aug; 33(34):e2102188. PubMed ID: 34278622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity.
    Yang S; Shim MK; Kim WJ; Choi J; Nam GH; Kim J; Kim J; Moon Y; Kim HY; Park J; Park Y; Kim IS; Ryu JH; Kim K
    Biomaterials; 2021 May; 272():120791. PubMed ID: 33831739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Red blood cell-based vaccines for ameliorating cancer chemoimmunotherapy.
    Su L; Hao Y; Li R; Pan W; Ma X; Weng J; Min Y
    Acta Biomater; 2022 Dec; 154():401-411. PubMed ID: 36241013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.